(121 days)
For in vitro diagnostic use only. VITROS Chemistry Products PCP Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi-quantitative or qualitative determination of phencyclidine (PCP) in human urine using a cutoff of 25 ng/mL. Measurements obtained with the VITROS PCP method are used in the diagnosis and treatment of phencyclidine use or overdose.
The VITROS Chemistry Products PCP assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result obtained with this assay. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.
For in vitro diagnostic use only. VITROS Chemistry Products Calibrator Kit 26 is used to calibrate VITROS 5,1 FS Chemistry Systems for the qualitative or semi-quantitative measurement of drugs of abuse.
For in vitro diagnostic use only. VITROS Chemistry Products FS Calibrator 1 is used in conjunction with VITROS Chemistry Products Calibrator Kits to calibrate VITROS 5,1 FS Chemistry Systems.
For in vitro diagnostic use only. VITROS Chemistry Products DAT Performance Verifiers are assayed controls used to monitor performance of urine drugs of abuse screening assays on VITROS 5,1 FS Chemistry Systems.
The VITROS PCP assay is a homogeneous enzyme immunoassay that is performed using the VITROS Chemistry Products PCP Reagent with the VITROS Chemistry Products Calibrator Kit 26, VITROS Chemistry Products FS Calibrator 1 and VITROS Chemistry Products FS Diluent Pack 4 (DAT Diluent / DAT Diluent 2) on VITROS 5,1 FS Chemistry Systems. The VITROS PCP Reagent is a dual chambered package containing ready-to-use liquid reagents that are used to detect phencyclidine in urine. Samples, calibrators, and controls are automatically treated with surfactant (DAT Diluent 2) prior to addition of reagents. Treated sample is added to Reagent 1 containing antibody reactive to phencyclidine, glucose-6-phosphate and nicotinamide adenine dinucleotide (NAD), followed by Reagent 2 containing phencyclidine labeled with the enzyme glucose-6-phosphate dehydrogenase (G6P-DH). The assay is based on competition between phencyclidine in the treated urine sample and phencyclidine labeled with the enzyme glucose-6-phosphate dehydrogenase (G6P-DH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, therefore the concentration of phencyclidine in the urine sample is directly proportional to measured enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically at 340 nm. VITROS Chemistry Products Calibrator Kit 26 is prepared from human urine to which drugs of abuse, metabolites of drugs of abuse, organic salt, surfactants, and preservative have been added. VITROS FS Calibrator 1 is prepared from sodium chloride and processed water. VITROS Calibrator Kit 26 is used in conjunction with VITROS FS Calibrator 1 to calibrate VITROS 5.1 FS Chemistry Systems for the qualitative or semi-quantitative measurement of phencyclidine (PCP). VITROS Chemistry Products DAT Performance Verifiers I. II, and V are prepared from a human urine pool to which analytes, surfactant, and preservative have been added. These are assaved controls used to monitor performance of the VITROS PCP assay on VITROS 5,1 FS Chemistry Systems. The VITROS Chemistry Products FS Diluent Pack 4 (DAT Diluent/ DAT Diluent 2) is a common reagent that is used with several drugs of abuse assays to dilute calibrators and samples on the VITROS 5,1 FS System. This is a dual chambered package containing two ready-to-use liquid diluents. DAT Diluent is prepared from human urine to which organic salt, surfactants, and preservative have been added. DAT Diluent 2 is prepared from processed water to which surfactant and preservative have been added. The VITROS 5,1 FS Chemistry System is a clinical chemistry instrument that provides automated use of the VITROS Chemistry Products MicroTip® and MicroSlides® range of products. The VITROS 5,1 FS System was cleared for market by 510(k) premarket notification (K031924).
This document describes the VITROS Chemistry Products PCP Reagent, VITROS Chemistry Products Calibrator Kit 26, VITROS Chemistry Products FS Calibrator 1, and VITROS Chemistry Products DAT Performance Verifiers, which are devices used for the semi-quantitative or qualitative determination of phencyclidine (PCP) in human urine.
Here's an analysis of the acceptance criteria and the study that proves the device meets them:
1. Table of Acceptance Criteria and Reported Device Performance:
The document doesn't explicitly list "acceptance criteria" as a separate section with specific numerical targets. Instead, it demonstrates the device's performance through comparison with legally marketed predicate devices. The primary acceptance criterion implicit in the 510(k) submission process is substantial equivalence to the predicate device.
The study aimed to show good agreement between the VITROS PCP assay and the predicate device (DADE BEHRING Syva® EMIT® II Plus Phencyclidine Assay).
| Device Characteristic | VITROS PCP Assay (New Device) Performance | Predicate Device (Syva® EMIT® II Plus Phencyclidine Assay) Performance | Acceptance Criteria (Implicit) |
|---|---|---|---|
| Intended Use | Qualitative and semi-quantitative analysis of phencyclidine in human urine. | Qualitative and semi-quantitative analysis of phencyclidine in human urine. | Substantially equivalent intended use. |
| Cut-Off Value | 25 ng/mL | 25 ng/mL | Match predicate device's cut-off value. |
| Sample Type | Human Urine | Human Urine | Match predicate device's sample type. |
| Reagent Format | Liquid ready to use | Liquid ready to use | Match predicate device's reagent format. |
| Antibody Source | Sheep polyclonal antibodies reactive to phencyclidine. | Sheep polyclonal antibodies reactive to phencyclidine. | Match predicate device's antibody source. |
| Calibration Traceability | Phencyclidine with confirmation by GC/MS | Phencyclidine with confirmation by GC/MS | Match predicate device's calibration traceability. |
| Calibrator Matrix | Human urine | Human urine | Match predicate device's calibrator matrix. |
| Control Matrix | Human urine | Human urine | Match predicate device's control matrix. |
| Agreement | "demonstrated good agreement" | N/A (predicate performance is the benchmark) | "Good agreement" with the predicate immunoassay method. |
| Reportable Range | 6.0 - 72.0 ng/mL | 8 - 90 ng/mL | Similar but not identical. The difference is acknowledged and implicitly acceptable for substantial equivalence. |
| Calibrator: Number of levels | Five | Qualitative: Three; Semi-quantitative: Five | Similar, with a consistent number for semi-quantitative use. |
| Calibrator Format | Frozen Liquid ready to use | Refrigerated liquid ready to use | Difference acknowledged and implicitly acceptable for substantial equivalence. |
| Instrumentation | VITROS 5,1 FS Chemistry Systems | Multiple automated clinical chemistry systems | Difference acknowledged and implicitly acceptable for substantial equivalence. |
| Control Claimed Analytes | More specific list focusing on PCP detection. | Broader list including more substances. | Difference acknowledged and implicitly acceptable for substantial equivalence, as the primary analyte (PCP) is consistent. |
| Control: Number of Levels | Three | Two | Difference acknowledged and implicitly acceptable for substantial equivalence. |
2. Sample Size Used for the Test Set and Data Provenance:
The document states: "Equivalence to the predicates was demonstrated using a commercially available assay along with patient samples."
- Test Set Sample Size: The exact number of "patient samples" used is not specified in the provided text.
- Data Provenance: The document does not explicitly state the country of origin. The use of "patient samples" implies these were real human urine samples, likely collected in a clinical setting. It is a retrospective or prospective study with patient samples, but the specific design isn't detailed beyond that.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications:
The document mentions "Calibration traceability: Phencyclidine with confirmation by GC/MS".
- Number of Experts: This information is not provided. GC/MS is an analytical method, not directly managed by "experts" in the sense of clinicians making diagnoses. While skilled laboratory personnel operate and interpret GC/MS results, the document doesn't quantify them or their specific qualifications.
- Qualifications of Experts: Not specified beyond the implication of trained laboratory personnel for GC/MS.
4. Adjudication Method for the Test Set:
- The document implies that Gas Chromatography/Mass Spectrometry (GC/MS) serves as the primary "ground truth" or confirmatory method. This is a highly accurate analytical technique. There is no mention of a traditional expert adjudication method (e.g., 2+1, 3+1) in the context of clinical expert agreement. The results of the VITROS PCP assay were compared to results obtained from the predicate device, which itself would have been validated against GC/MS.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
- No MRMC study was done. This device is an automated in vitro diagnostic (IVD) assay. Its performance is compared to another automated IVD assay and a reference method like GC/MS, not to human readers' interpretations. Therefore, there's no concept of human readers improving with AI assistance in this context.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study:
- Yes, a standalone study was done. The entire comparison described is a standalone performance assessment of the VITROS PCP assay (an "algorithm" in the sense of an automated test) against a predicate device and ground truth (GC/MS) without human-in-the-loop interpretation as a primary measure. The instrument ("VITROS 5,1 FS Chemistry Systems") automates the process.
7. Type of Ground Truth Used:
- The primary ground truth used is phencyclidine concentration confirmed by Gas Chromatography/Mass Spectrometry (GC/MS). The document explicitly states: "Phencyclidine with confirmation by GC/MS" under "Calibration traceability." GC/MS is considered the "preferred confirmatory method" for drug-of-abuse test results.
8. Sample Size for the Training Set:
- The document does not provide information on a separate "training set" or its size. As this is an in vitro diagnostic device, the "training" for the assay itself would involve optimization during development, rather than a distinct machine learning-style training set of clinical data after the assay's chemical formulation is finalized. Calibrators are defined, but these aren't typically referred to as a "training set" in the context of machine learning.
9. How the Ground Truth for the Training Set Was Established:
- As a distinct "training set" is not mentioned in the provided text, the method for establishing its ground truth is not applicable/not provided. The calibrators (VITROS Chemistry Products Calibrator Kit 26 and VITROS Chemistry Products FS Calibrator 1) are prepared from human urine with drugs of abuse added, and their values are established through reference methods (implied to be traceable to GC/MS for phencyclidine). These calibrators are used to establish the measurement curve for the assay.
{0}------------------------------------------------
Not & & 200h
Image /page/0/Picture/1 description: The image shows the logo for Ortho-Clinical Diagnostics. The logo consists of a stylized symbol to the left of the text "Ortho-Clinical Diagnostics". The symbol appears to be a stylized representation of a medical or scientific emblem. The text is in a simple, sans-serif font, with "Ortho-Clinical" on the top line and "Diagnostics" on the bottom line.
Johnson-Johnson company
100 Indigo Creek Drive Rochester, New York 14626-5101
510(k) Summary This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: ب 06 -2 06 -2 09 4 Ortho-Clinical Diagnostics, Inc. 1. Submitter 100 Indigo Creek Drive name, Rochester, New York 14626-5101 address. (585) 453-4253 contact Contact Person: Darlene Phillips 2. Preparation September 28, 2006 Date 3. Device name Trade or Proprietary Names: VITROS Chemistry Products PCP Reagent VITROS Chemistry Products Calibrator Kit 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, & V Common Names: Phencyclidine (PCP) assay and controls Classification Names: Phencyclidine test system (862.3100) Class II Clinical toxicology calibrators (862.3200) Class II Clinical toxicology control material (862.3280) Class I, VITROS DAT Performance Verifiers are assayed controls, so they meet the reserved criteria under Section 510(1) of the Food, Drug and Cosmetic Act. 4. Predicate The VITROS Chemistry Products PCP assay is substantially equivalent to the DADE BEHRING Syva® EMIT® II Plus Phencyclidine Assay. Devices The VITROS Chemistry Products DAT Performance Verifiers are substantially equivalent to the BIO-RAD Liquichek™ Urine Toxicology Controls.
Continued on next page
{1}------------------------------------------------
5. Device The VITROS PCP assay is a homogeneous enzyme immunoassay that is description performed using the VITROS Chemistry Products PCP Reagent with the VITROS Chemistry Products Calibrator Kit 26, VITROS Chemistry Products FS Calibrator 1 and VITROS Chemistry Products FS Diluent Pack 4 (DAT Diluent / DAT Diluent 2) on VITROS 5,1 FS Chemistry Systems. The VITROS PCP Reagent is a dual chambered package containing ready-to-use liquid reagents that are used to detect phencyclidine in urine. Samples, calibrators, and controls are automatically treated with surfactant (DAT Diluent 2) prior to addition of reagents. Treated sample is added to Reagent 1 containing antibody reactive to phencyclidine, glucose-6-phosphate and nicotinamide adenine dinucleotide (NAD), followed by Reagent 2 containing phencyclidine labeled with the enzyme glucose-6-phosphate dehydrogenase (G6P-DH). The assay is based on competition between phencyclidine in the treated urine sample and phencyclidine labeled with the enzymc glucose-6-phosphate dehydrogenase (G6P-DH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, therefore the concentration of phencyclidine in the urine sample is directly proportional to measured enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically at 340 nm. VITROS Chemistry Products Calibrator Kit 26 is prepared from human urine to which drugs of abuse, metabolites of drugs of abuse, organic salt, surfactants, and preservative have been added. VITROS FS Calibrator 1 is prepared from sodium chloride and processed water. VITROS Calibrator Kit 26 is used in conjunction with VITROS FS Calibrator 1 to calibrate VITROS 5.1 FS Chemistry Systems for the qualitative or semi-quantitative measurement of phencyclidine (PCP). VITROS Chemistry Products DAT Performance Verifiers I. II, and V are prepared from a human urine pool to which analytes, surfactant, and preservative have been added. These are assaved controls used to monitor performance of the VITROS PCP assay on VITROS 5,1 FS
Chemistry Systems.
Continued on next page
{2}------------------------------------------------
.
| 4. Devicedescription(continued) | The VITROS Chemistry Products FS Diluent Pack 4 (DAT Diluent/DAT Diluent 2) is a common reagent that is used with several drugs ofabuse assays to dilute calibrators and samples on the VITROS 5,1 FSSystem. This is a dual chambered package containing two ready-to-useliquid diluents. DAT Diluent is prepared from human urine to whichorganic salt, surfactants, and preservative have been added. DATDiluent 2 is prepared from processed water to which surfactant andpreservative have been added. |
|---|---|
| The VITROS 5,1 FS Chemistry System is a clinical chemistryinstrument that provides automated use of the VITROS ChemistryProducts MicroTip® and MicroSlides® range of products. The VITROS5,1 FS System was cleared for market by 510(k) premarket notification(K031924). | |
| 6. Deviceintended uses | VITROS Chemistry Products PCP Reagent: For in vitro diagnosticuse only. VITROS Chemistry Products PCP Reagent is used on VITROS5,1 FS Chemistry Systems for the semi-quantitative or qualitativedetermination of phencyclidine (PCP) in human urine using a cutoff of25 ng/mL. Measurements obtained with the VITROS PCP method areused in the diagnosis and treatment of phencyclidine use or overdose. |
| The VITROS Chemistry Products PCP assay is intended for use byprofessional laboratory personnel. It provides only a preliminary testresult. A more specific alternative chemical method must be used toconfirm a result obtained with this assay. Gas chromatography/massspectrometry (GC/MS) is the preferred confirmatory method. Clinicalconsideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positiveresult. | |
| VITROS Chemistry Products Calibrator Kit 26: For in vitrodiagnostic use only. VITROS Chemistry Products Calibrator Kit 26 isused to calibrate VITROS 5,1 FS Chemistry Systems for the qualitativeor semi-quantitative measurement of drugs of abuse. | |
| VITROS Chemistry Products FS Calibrator 1: For in vitro diagnosticuse only. VITROS Chemistry Products FS Calibrator 1 is used inconjunction with VITROS Chemistry Products Calibrator Kits tocalibrate VITROS 5,1 FS Chemistry Systems. | |
| VITROS Chemistry Products DAT Performance Verifiers I, II, andV: For in vitro diagnostic use only. VITROS Chemistry Products DATPerformance Verifiers are assayed controls used to monitor performanceof urine drugs of abuse screening assays on VITROS 5,1 FS ChemistrySystems. | |
| Continued on next page |
{3}------------------------------------------------
7. Comparison The VITROS Chemistry Products PCP assay and VITROS Chemistry to predicate Products DAT Performance Verifiers are substantially equivalent to the DADE BEHRING Syva® EMIT® II Plus Phencyclidine Assay devices (K993983) and BIO-RAD Liquichek" 31 Urine Toxicology Controls (K022707) (predicate devices) which were cleared by the FDA for in vitro diagnostic use.
The performance of the VITROS PCP assay on the VITROS 5.1 FS Chemistry System was compared to the Syva® EMIT® II Plus Phencyclidine assay on the Syva® 30R Biochemical System. The results demonstrated good agreement between the two immunoassay methods.
The VITROS PCP assay and the VITROS DAT Performance Verificrs have the following similarities to the predicate devices: the same intended use, the same cutoff value of 25 ng/mL, consist of liquid, ready to use reagents, have similar performance characteristics, are used on an automated clinical chemistry analyzer and calibrated against the same drug, phencyclidine.
- Similarities and differences of the assays performed using the VITROS Table 1 PCP assay and the VITROS DAT Performance Verifiers and the EMIT® Phencyclidine assay and BIO-RAD® Liquichek114 Urine Toxicology Controls.
| Device Similarities | |
|---|---|
| Device Characteristic | Description |
| Indications for Use | The assays are intended for use in the qualitative and semi-quantitative analysis of phencyclidine in human urine. |
| Calibration traceability | Phencyclidine with confirmation by GC/MS |
| Cut-Off value | 25 ng/mL |
| Sample Type | Human Urine |
| Reagent Format | Liquid ready to use |
| Antibody source | Sheep polyclonal antibodies reactive to phencyclidine |
| Calibration traceability | Phencyclidine with confirmation by GC/MS |
| Calibrator matrix | Human urine |
| Control matrix | Human urine |
Continued on next page
{4}------------------------------------------------
| Differences | ||
|---|---|---|
| DeviceCharacteristic | VITROS PCP assay(New device) | EMIT® Phencyclidine assay andLiquichek™ Urine ToxicologyControls(Predicate devices) |
| Reportable Range | 6.0 - 72.0 ng/mL | 8 - 90 ng/mL |
| Calibrator: Number oflevels | Five | Qualitative: ThreeSemi-quantitative: Five |
| Calibrator format | Frozen Liquid ready to use | Refrigerated liquid ready to use |
| Instrumentation | To be used on VITROS 5,1 FSChemistry Systems | Multiple automated clinicalchemistry systems |
| Control claimedanalytes | Cocaine metabolites(benzoylecgonine),benzodiazepines(lormetazepam), methadone,amphetamines (d-methamphetamine), opiates(morphine), cannabinoids (11-nor-delta-THC-9-COOH),phencyclidine and barbiturates(secobarbital). | Methamphetamine, secobarbital,lormetazepam,tetrahydrocannabinol (THC),benzoylecgonine, ethanol,lysergic acid diethylamide (LSD),methadone, methaqualone,morphine, (Free), phencyclidine,propoxyphene, nortriptyline andaddition of creatinine, pH,specific gravity. |
| Control: Number oflevels | Three | Two |
-
- Conclusions The data presented in the premarket notification provide a reasonable assurance that the VITROS Chemistry Products PCP Reagent, VITROS Chemistry Products Calibrator Kit 26, VITROS Chemistry Products FS Calibrator 1 and VITROS Chemistry Products DAT Performance Verifiers are safe and effective for the stated intended uses and are substantially equivalent to the cleared predicate devices. Equivalence to the predicates was demonstrated using a commercially available assay along with patient samples.
{5}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle or bird-like symbol with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the symbol. The logo is black and white.
Public Health Service
Food and Druq Administration 2098 Gaither Road Rockville MD 20850
Ms. Darlene Phillips Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive Rochester, New York 14626-5101
NOV 2 2 2006
Rc: K062094
Trade/Device Name: VITROS Chemistry Products PCP Reagent Regulation Number: Unclassified Regulation Name: Enzyme immunoassay, phencyclidine Regulatory Class: 510(k) required Product Code: LCM, DKB, DIF Dated: September 28, 2006 Received: September 29, 2006
Dear Ms. Phillips:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{6}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Alberto Garcia
Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
Indications for Use
Page 1 of 2
510(k) Number (if known):
KOG 2094
Device Name: VITROS Chemistry Products PCP Reagent
Indications For in vitro diagnostic use only. VITROS Chemistry Products PCP for Use: Reagent is used on VITROS 5,1 FS Chemistry Systems for the semiquantitative or qualitative determination of phencyclidine (PCP) in human urine using a cutoff of 25 ng/mL. Measurements obtained with the VITROS PCP method are used in the diagnosis and treatment of phencyclidine use or overdose.
The VITROS Chemistry Products PCP assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result obtained with this assay. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drugof-abuse test result, particularly when evaluating a preliminary positive result.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safe
KD62094
{8}------------------------------------------------
Indications for Use
Page 2 of 2
510(k) Number (if known):
KO62094
Device Name: VITROS Chemistry Products Calibrator Kit 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, and V
Indications For in vitro diagnostic use only. VITROS Chemistry Products Calibrator for Use: Kit 26 is used to calibrate VITROS 5,1 FS Chemistry Systems for the qualitative or semi-quantitative mcasurement of drugs of abuse.
For in vitro diagnostic use only. VITROS Chemistry Products FS Calibrator 1 is used in conjunction with VITROS Chemistry Products Calibrator Kits to calibrate VITROS 5,1 FS Chemistry Systems.
For in vitro diagnostic use only. VITROS Chemistry Products DAT Performance Verifiers are assayed controls used to monitor performance of urine drugs of abuse screening assays on VITROS 5,1 FS Chemistry Systems.
Prescription Use _______________ AND/OR Over-The-Counter Use __ (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off
Office of In Vitro Dirgnostic Device Evaluation and Safe
N/A